Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTRMWXHS-12 in Relapsed/Refractory Mantle Cell Lymphoma
NCT03836768Phase 1Completed
- Sponsor
- DTRM Biopharma
- Start
- Jan 2019
- Primary completion
- Nov 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Multivalent & Scaffold-Based Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DTRMWXHS-12 in mantle cell lymphoma (MCL), sponsored by DTRM Biopharma. Primary endpoint: Incidence and severity of (serious) adverse events. Started Jan 2019; status: completed.
02
Drugs
DTRMWXHS-12
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03836768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836768.